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Abstract 
The linear haemagglutinin noose epitope (HNE; aa 379–410) is a protective B-cell epitope and 
considered to be highly conserved in both the vaccine and the wild-type measles virus (MeV) 
haemagglutinin (H) proteins. Vaccine virus-derived monoclonal antibodies (mAbs) BH6 and BH216, 
which target the HNE, neutralized MeVs of genotypes B3, C2, D4, D5, D6, D7 and D8, and the 
vaccine strain Edmonston Zagreb. In the case of genotype H1, only strain Berlin.DEU/44.01 was 
neutralized by these mAbs, whereas strains Shenyang.CHN/22.99 and Sofia.BGR/19.05 were not. 
The H gene sequences of these two strains showed an exchange of proline 397 (P397) to leucine 
(L397). Mutated H proteins, with P397 exchanged to L and vice versa, were compared with original H 
proteins by indirect fluorescence assay. H proteins exhibiting P397 but not those with L397 were 
recognized by BH6 and BH216. This indicates that L397 leads to the loss of the neutralizing HNE. In 
contrast, human sera obtained from vaccinees (n=10) did not discriminate between genotype H1 
variants P397 and L397. This concurs with the epidemiological observation that the live-attenuated 
vaccine protects against both H1 variants. Furthermore, we demonstrated that MeVs of genotype H1 
also lack the neutralizing epitopes defined by the vaccine virus-induced mAbs BH15, BH125 and 
BH47. The loss of several neutralizing epitopes, as shown for H1 viruses currently circulating 




Vaccination with a live-attenuated measles vaccine elicits long-lasting immunity that involves humoral, 
cellular and mucosal responses. Protection from (re)infection is mediated by both antibodies specific 
for measles virus (MeV) and circulating MeV-specific T cells (Duke & Mgone, 2003). Neutralizing 
antibodies are directed against the two viral surface glycoproteins, the haemagglutinin (H) and the 
fusion (F) protein. These antibodies block the interaction of the H protein with its cellular receptors and 
the fusion activity (Bouche et al., 2002). It has recently been demonstrated that H-specific antibodies 
are the main link to vaccine-induced MeV neutralization (de Swart et al., 2005). They are mainly 
directed against conformational epitopes of the H protein (Bouche et al., 2002). However, vaccine 
virus-derived monoclonal antibodies (mAbs) BH6 and BH216 neutralize MeVs of various genotypes 
efficiently by recognizing the linear haemagglutinin noose epitope (HNE; aa 379–410) (Ertl et al., 
2003; Santibanez et al., 2005; Ziegler et al., 1996). The HNE domain contains three cysteine residues 
(C381, C386 and C394) forming a surface-exposed loop (Ziegler et al., 1996). Binding studies with a 
panel of mutated peptides representing the HNE sequence of several wild-type MeVs suggest that 
MeV-neutralizing and protective mAbs bind to the motif X7C[KR]GX[AINQ]QX2CEX5 (aa 379–400) 
(Putz et al., 2003). Peptides mimicking the HNE induced high levels of antibodies neutralizing MeVs of 
  
all genotypes in mice. Therefore, the HNE was proposed as a promising peptide vaccine for infants 
that could cover the interval between waning maternal immunity and protection by the live-attenuated 
measles, mumps, rubella (MMR) vaccine (Bouche et al., 2003, 2005; El Kasmi et al., 2000; Ziegler et 
al., 1996). The HNE is highly conserved among wild-type MeVs, although some field isolates with 
mutations have been reported. This study addresses the question of whether these variants are still 
recognized by HNE-specific mAbs.  
Elimination of measles has been achieved in highly vaccinated populations irrespective of the 
molecular genetic characteristics of imported MeVs. This indicates that the immune responses 
induced by the live-attenuated vaccine virus protect against current wild-type MeVs. In an earlier study 
we reported that most neutralizing epitopes of the H protein were shared between vaccine and wild-
type MeVs (Santibanez et al., 2005), although some were lost from wild-type MeVs isolated in Europe 
between 2000 and 2002. In this study, MeVs currently imported from Africa and Asia and causing 
large outbreaks in Europe were investigated with respect to the conservation of the immunodominant 
HNE. Our results demonstrate that the HNE of several genotype H1 MeVs was not recognized by 
mAbs derived from vaccine virus, and that other neutralizing epitopes of H1 viruses were lost.  
 
Methods 
Nucleotide sequence determination of the MeV H coding region. 
Viral RNA was reverse transcribed using primer MeH1 (5′-CCTCTGGCCGAACAATATCG) and 
reverse transcriptase Superscript III (Invitrogen). A fragment containing the coding region of the H 
protein was amplified from cDNA by nested PCR using the Phusion high-fidelity PCR kit (New England 
Biolabs). Primers MeH1 and MeH6 (5′-CAGATAGCGAGTCCATAACG) were used for the first round 
and MeH3 (5′-CTTAGGGTGCAAGATCATCC) and MeH8 (5′-GGTATGCCTGATGTCTGG) for the 
second amplification round. Amplified DNA was sequenced with an ABI Prism Big Dye Terminator 
cycle sequencing kit (PerkinElmer) using forward primers MeH3 and MeH5 (5′-




The cDNA of the H gene of MeV isolates Berlin.DEU/44.01 and Sofia.BGR/19.05 and the Edmonston 
Zagreb vaccine was cloned into vector pCMV-HA (Clontech) and pcDNA3.1 (Invitrogen). All cloning 
steps were performed according to standard techniques (Sambrook & Russell, 2001). DNA fragments 
were amplified via standard PCR techniques using the Phusion high-fidelity PCR kit and restriction 
site-tagged primers. The H protein coding region of MeV H1 strains were amplified with primer pair 
Me-76 (5′-CGGAATTCGGATGTCACCACAACGAGACCGGAT) and Me-79 (5′-
CGGGGTACCCTATCTGTGATTGGTTCCATCTTC), whereas that of Edmonston Zagreb was 
amplified with primers Me-76 and Me-78 (5′-CGGGGTACCCTATCTGTGATTGGTTCCATCTTC). 
Cycling parameters were 94 °C, 2 min; 30× (94 °C, 15 s; 60 °C, 30 s; 72 °C, 45 s); 72 °C, 7 min. PCR 
products were inserted via the introduced EcoRI and KpnI restriction sites into pCMV-HA and 
sequenced with the plasmid-specific primers 1219 (5′-GGATGTTGCCTTTACTTCTAG) and 1270 (5′-
ATAAAGCATTTTTTTCACTGCATTC). H genes were subcloned into pcDNA3.1 via EcoRI and NotI 
and subsequently mutated with the QuikChange II site-directed mutagenesis kit (Stratagene). To 
mutate the H genes of the respective MeVs, we used primer pair Ma-80 (5′-
AGCACTCTGCGAGAATCTCGAGTGGGCACCATTGA) and Ma-81 (5′-
TCAATGGTGCCCACTCGAGATTCTCGCAGAGTGCT) for strain Edmonston Zagreb; primer pair Ma-
82 (5′-AGCACTCTGTGAAAATCTCGAGTGGGCACCGTTGA) and Ma-83 (5′-
TCAACGGTGCCCACTCGAGATTTTCACAGAGTGCT) for strain Berlin.DEU/44.01 and primer pair 
Ma-84 (5′-AGCACTCTGTGAAAATCCCGAGTGGGCACCGTTGA) and Ma-85 (5′-
TCAACGGTGCCCACTCGGGATTTTCACAGAGTGCT) for isolate Sofia.BGR/19.05. All pcDNA3.1 
constructs were sequenced with the plasmid-specific primers T7 (5′-TAATACGACTCACTATAGGG) 
and BGH (5′-TAGAAGGCACAGTCGAGG).  
  
 
Immunofluorescence analysis (IFA). 
HEK-293 cells were grown on coverslips in 24-well plates. Transfection was performed with Effectene 
transfection reagent (Qiagen). For each transfection, a total of 200 ng plasmid DNA was used. At 48 h 
post-transfection (p.t.), cells were washed with PBS and fixed with 4  % paraformaldehyde in PBS for 
10 min at room temperature, afterwards cells were permeabilized with 0.1  % Triton X-100 in PBS for 
10 min. Cells were blocked for 1 h with blocking solution (PBS, 0.05 % Tween 20, 1 % BSA) and 
incubated with 10 μg ml
−1
 of the respective primary antibody for 1 h at room temperature. After three 
washing steps with PBS-T (0.05 % v/v), cells were incubated with fluorescein isothiocyanate (FITC)-
conjugated secondary antibody at 15 μg ml
−1
 (Dianova) for 1 h at room temperature. Coverslips were 
washed three times with PBS-T, mounted in Mowiol (Merck) and examined with a confocal 
laserscanning microscope (cLSM 510, Zeiss).  
 
Focus of infection reduction neutralization test (FRNT). 
H-specific mAbs were diluted by fd×2
n
 (fd=mAb-specific dilution factor, n=1, 2, 3, 4, 5 and 6) in MEM 
alpha medium (Invitrogen) supplemented with 5 % fetal calf serum (FCS). MeV suspensions containing 
40–60 p.f.u. per 100 μl were incubated with serially diluted mAbs and incubated for 60 min at 37 °C. 
Aliquots (100 μl) were transferred onto a confluent monolayer of signalling lymphocytic activation 
molecule (SLAM)-transduced Chinese hamster ovary (CHO) cells and incubated at 37 °C for 60 min. 
The inoculum was removed and the cells were covered with an overlay containing 0.5  % CM cellulose 
and 3 % FCS and incubated for 3 days. MeV-infected cells were detected by the use of an indirect 
immunocolorimetric assay, which has been previously described for detection of rubella virus (Chen et 
al., 2007). Cells were fixed with 2 % paraformaldehyde in PBS and permeabilized with ice-cold 
methanol (at −20 °C). MeV-infected cells were detected using the mAb NP cl.120 directed against the 
MeV nucleocapsid (N) protein (hybridoma cells were kindly provided by T. F. Wild, Institute Pasteur de 
Lyon, France) as primary antibody, goat anti-mouse IgG peroxidase conjugate (Chemicon 
International) as secondary antibody and tetramethylbenzidine (Mikrogen) as precipitating peroxidase 
substrate. Foci of MeV infection are visible to the naked eye as dark blue spots, which were counted. 
For each MeV, the number of foci of infection was determined in the absence of antibody. The amount 
of IgG per well resulting in 50 % reduction of the foci number was calculated. All tests were performed 
in triplicate and repeated at least twice. FRNT tests with human sera were performed as described for 
mAbs, except that sera were diluted by 5×2
n
 (n=1, 2, 3, 4, 5, 6 and 7). Sera obtained from 10 
vaccinated individuals were chosen from a panel collected from 13–15-year-old students in the scope 
of the seroprevalence study SCARPOL which was recently performed in Switzerland (Tischer et al., 
2007). All serum donors had received two doses of MMR vaccine, the second dose had been 




The HNE is not universally conserved among MeVs 
To study the presence of the HNE on contemporary MeVs, an FRNT was performed using the two 
HNE-specific mAbs BH6 and BH216. These mAbs blocked infection of SLAM-transduced CHO cells 
(Erlenhoefer et al., 2001) by MeV isolates of the genotypes B3, C2, D4, D5, D6, D7 and D8 plus the 
vaccine virus Edmonston Zagreb (Table 1⇓). When MeVs of genotype H1 were investigated, BH6 and 
BH216 neutralized Berlin.DEU/44.01 efficiently, while Shenyang.CHN/22.99 and Sofia.BGR/19.05 
were able to infect the cells in presence of the mAbs. This result indicates that the HNE is not 
universally conserved and heterologous between the genotype H1 viruses.  
The neutralizing capacity of the mAbs was determined by FRNT on SLAM-expressing CHO cells. 





MeVs of genotype H1 show diversity in the HNE sequence 
The nucleotide sequence of the H gene of all MeVs used in this study was determined and correlated 
with the results of the FRNT. The sequence alignment revealed three amino acid exchanges, but only 
that at aa 397 was unique for Shenyang.CHN/22.99 and Sofia.BGR/19.05. L397 was seen for 
Shenyang.CHN/22.99 and Sofia.BGR/19.05, while P397 was found in Berlin.DEU/44.01 and all other 
MeVs included in our study. This mutation is located within the HNE sequence (aa 379–410) (Table 
2⇓) and our observation implied that P397L influenced recognition of H by mAbs BH6 and BH216. A 
search for MeV H protein sequences deposited in GenBank showed that MeVs of all genotypes 
exhibited P397 (data not shown), with the exception of one D6 (Ser397, derived from a subacute 
sclerosing panencephalitis case) and several H1 MeVs. Amongst genotype H1, both sequence 
variants P397 and L397 were seen: 23 sequences of the L397 variant were found, while 21 
sequences carried the P397. Based on these findings, L397 in the HNE seems to be restricted to 
genotype H1 viruses.  
 
The presence of P397 is critical for binding of vaccine virus-induced HNE-directed mAbs 
H proteins from several genotypes were cloned into plasmid pCMV-HA. The constructs were 
transfected into HEK-293 cells. At 24 h p.t., cells were fixed and the expression of H protein was 
tested with mAbs BH17, BH6 and BH216. The findings corroborated the FRNT result, since BH6 and 
BH216 did not react with the H protein of Sofia.BGR/19.05 (Fig. 1⇓) and Shenyang.CHN/22.99 (data 
not shown). This approach was used to investigate the effect of P397L on the recognition of the HNE 
by mAbs BH6 and BH216. P was changed to L in H proteins of the Edmonston Zagreb vaccine and 
MeV Berlin.DEU/44.01, while the reciprocal exchange of L397P was introduced into the H protein of 
Sofia.BGR/19.05. The mutated H proteins were expressed in HEK-293 cells and tested by IFA. The 
mAb BH17 was used as a positive control and recognized all H variants. All H proteins carrying P397 
were detected by BH6 and BH216 regardless of their genotype (Fig. 1⇓), while those displaying L397 
were not.  
 
Analysis of neutralizing epitopes shared by genotype H1 and vaccine MeVs 
To identify further differences in neutralizing epitopes of the H protein between the H1 MeVs 
(Berlin.DEU/44.01, Shenyang.CHN/22.99 and Sofia.BGR/19.05) and the Edmonston Zagreb vaccine, 
other vaccine virus-induced mAbs (BH15, BH17, BH47, BH67, BH81, BH125 and BH141) were used 
in an FRNT in addition to BH6 and BH216. These mAbs recognized additional epitopes of the H 
protein: mAbs BH17, BH67, BH81 and BH141 neutralized the vaccine as well as genotype H1 viruses 
with high efficiency (Table 3⇓). It was shown previously that BH17 and BH141, as well as BH67 and 
BH141, competed for binding sites on the H protein (Bouche et al., 2002). All mAbs recognize 
conformational epitopes with the exception of mAb BH47 which binds to a linear epitope (aa 244–250) 
(Fournier et al., 1997). BH47 neutralized all four viruses, except Shenyang.CHN/22.99, with a very low 
efficiency, indicating that the linear epitope defined by mAb BH47 is heterologous between the 
genotype H1 viruses. In contrast, mAb BH15 and BH215 neutralized the vaccine virus with variable 
efficiency but did not interfere with genotype H1 infection. In summary, our investigation identified two 
neutralizing epitopes of the H protein, which are shared by genotype H1 and vaccine MeVs. These 
epitopes are considered as conformational.  
 
Sera from vaccinated individuals do not discriminate between H protein variants P397 and 
L397 
Sera with low levels of MV-specific IgG of 10 vaccinated individuals were tested in FRNTs against the 
genotype H1 virus isolates Berlin.DEU/44.01 (P397) and Sofia.BGR/19.05 and vaccine virus 
Edmonston Zagreb (P397) to determine if their neutralizing capacity was affected by the absence of 
the HNE. The differences in neutralization titres measured for each serum were less than fourfold, 
which is below the level of significance (Table 4⇓). These data suggest that vaccine-induced 




Surveillance data do not provide any indication for the emergence of escape mutants from vaccine-
induced neutralizing antibodies in humans. However, the pattern of neutralizing epitopes on the H 
protein of currently circulating wild-type MeV differs between strains and compared with the vaccine 
virus.  
For the HNE, though it is a surface-exposed target of strongly neutralizing antibodies and is thus 
assumed to be under a continuous pressure for change, previous studies reported a high degree of 
conservation between all genotypes (El Kasmi et al., 2000; Putz et al., 2003), corroborating the 
hypothesis that alterations in the HNE might interfere with the functionality of H protein. Neutralization 
assays showed that vaccine virus-induced mAbs BH6 and BH216, which target the HNE, were able to 
neutralize 14 wild-type MeVs of different genotypes (B3, C2 and D4–D8). In the case of genotype H1, 
Berlin.DEU/44.01 was neutralized, but Shenyang.CHN/22.99 and Sofia.BGR/19.05 were not. 
Sequence analysis revealed a P397L change in these two strains. IFA demonstrated that BH6 and 
BH216 exclusively recognized H proteins containing P397, both original and mutant, indicating that 
this position is critical for recognition of the HNE. The implications of the L397 variant are not easy to 
assess, but results obtained for other viruses point at a certain risk potential regarding escape from 
antibodies provided by vaccination or previous infection. In the case of influenza virus type A, a 
proline-to-leucine/histidine point mutation in the ectodomain of the transmembrane protein M2 
emerged that permitted escape from antibody recognition (Zharikova et al., 2005).  
Previous results obtained by a competition study between mAbs and human serum antibodies 
identified the HNE as one of two main targets of human antibodies. The second one, an epitope 
recognized by mAbs BH26, BH67 and BH81, might be associated with SLAM (Ertl et al., 2003). Our 
study detected two epitopes that were still conserved between all genotypes tested, one that was 
recognized by the strongly neutralizing mAbs BH17 and BH141, and the supposedly SLAM-associated 
epitope mentioned above. The presence of conserved epitopes may be responsible for the continued 
protection provided by the measles vaccine, also against MeV variants that have lost the HNE epitope. 
This was confirmed on a serological level by FRNT tests we performed with a set of human sera from 
vaccinees, which did not discriminate between the genotypes used.  
In contrast with our study employing the complete H protein, mAb BH216 bound with equal affinity to 
HNE peptides (aa 379–400) regardless of whether they exhibited P397 or L397 (Putz et al., 2003). 
When mice were immunized with a polyepitope vaccine containing eight copies of the HNE, the 
antiserum neutralized not only MeV isolate China94-1 encoding P397 but also MeV isolate China93-2 
(L397) (Bouche et al., 2005). Thus, it is possible to speculate that P397 is critical for binding of BH216 
and also that the nature of the antigen influences recognition by altering the folding of the polyepitope 
or the protein differentially. A database search in 2005 revealed that only 2  % of MeV H sequences 
contained L397 (Putz et al., 2003). Analysis of the H protein sequences currently published in 
GenBank revealed that L397 was restricted to genotype H1, the MeV genotype predominantly 
circulating in China. More than 109 000 cases were reported from China in 2007, representing 39  % of 
the global measles cases (Bian et al., 2006; Liffick et al., 2001; Xu et al., 1998; Yu et al., 2007; Zhang 
et al., 2008). H1 has also been observed in Korea and Japan (Na et al., 2003; Nakayama et al., 2003; 
Tomita, 2006; Zhou et al., 2003). In China, both H variants, P397 and L397, have been found since 
1993 whereas in Korea and Japan, only the L397 variant has been detected in samples collected 
since 2000.  
MeVs with a partial loss of immunodominant epitopes like the HNE are still effectively neutralized by 
vaccine-induced polyclonal human sera, but as additional losses might reduce the efficacy of 
vaccination, we suggest implementation of epitope monitoring into measles surveillance. In this 
context, the acceleration of the measles elimination process by vaccination is a principle strategy to 
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Table 1.  Neutralizing capacity of HNE-specific mAbs 
The neutralizing capacity of the mAbs was determined by FRNT on SLAM-expressing CHO cells. 







Table 2. Sequence comparison of the HNE (aa 379–410) found within the H protein of different 
MV genotypes used in this study 









Table 3. Capacity of anti-H mAbs to neutralize MeV isolates of genotype H1 compared with the 
Edmonston Zagreb vaccine virus 
The neutralizing capacity of the mAbs was determined by FRNT on SLAM-expressing CHO cells. 







Table 4. Capacity of human sera to neutralize MeV isolates of the distinct H protein variants of 
genotype H1 
Sera were collected from 10 vaccinees (V1–V10). Each serum was tested by FRNT on SLAM-
expressing CHO cells against MeV isolates of genotype H1 representing the H protein variants P397 
(Berlin.DEU/44.01) and L397 (Sofia.BGR/19.05), and the vaccine virus Edmonston Zagreb (P397). 
Values of neutralizing capacity are expressed as serum titre resulting in 50 % reduction of number of 
foci of MeV infection. The genotype and amino acid found at position 397 are given in Table 3.  
 
*MeV-specific IgG was determined by enzyme immunoassay (Enzygnost, Dade Behring).
  
Figure 1. The H proteins of the vaccine strain Edmonston Zagreb (P397), Berlin.DEU/44.01 (P397) 
and Sofia.BGR/19.05 (L397) were cloned into pcDNA3.1. Additionally, point mutants of H were 
produced in which P397L and L397P were introduced. HEK-293 cells were transfected with the 
indicated plasmids. At 48 h p.t., cells were fixed and the reactivity of HNE-specific mAbs BH6 and 
BH216 was tested by IFA. mAb BH17, which is specific for all H protein variants, was used as a 
positive control.  
 
 
